Pharmacokinetics of Macrolide Antibiotics and Transport into the Interstitial Fluid: Comparison among Erythromycin, Clarithromycin, and Azithromycin
暂无分享,去创建一个
T. Sakaeda | Yukako Ito | K. Maeda | S. Kobuchi | T. Kabata
[1] T. Sakaeda,et al. Pharmacokinetics and lung distribution of macrolide antibiotics in sepsis model rats , 2020, Xenobiotica; the fate of foreign compounds in biological systems.
[2] Zhixin Liang,et al. The species distribution, antimicrobial resistance and risk factors for poor outcome of coagulase-negative staphylococci bacteraemia in China , 2019, Antimicrobial Resistance & Infection Control.
[3] A. Walker,et al. The challenge of antimicrobial resistance: What economics can contribute , 2019, Science.
[4] I. Senta,et al. Comprehensive determination of macrolide antibiotics, their synthesis intermediates and transformation products in wastewater effluents and ambient waters by liquid chromatography-tandem mass spectrometry. , 2017, Journal of chromatography. A.
[5] A. Kuwahara,et al. Transport of Azithromycin into Extravascular Space in Rats , 2016, Antimicrobial Agents and Chemotherapy.
[6] T. Sakaeda,et al. Therapeutic Drug Monitoring of Vancomycin in Dermal Interstitial Fluid Using Dissolving Microneedles , 2016, International journal of medical sciences.
[7] T. Sakaeda,et al. Application of dissolving microneedles to glucose monitoring through dermal interstitial fluid. , 2014, Biological & pharmaceutical bulletin.
[8] P. Rudzki,et al. Simplified LC-MS/MS method enabling the determination of azithromycin in human plasma after a low 100mg dose administration. , 2014, Journal of pharmaceutical and biomedical analysis.
[9] M. Zeitlinger,et al. Development of a Population Pharmacokinetic Model Characterizing the Tissue Distribution of Azithromycin in Healthy Subjects , 2014, Antimicrobial Agents and Chemotherapy.
[10] K. Tateda,et al. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia. , 2014, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[11] K. Morimoto,et al. Subcellular distribution of azithromycin and clarithromycin in rat alveolar macrophages (NR8383) in vitro. , 2013, Biological & pharmaceutical bulletin.
[12] M. Kinzig,et al. Blood, Tissue, and Intracellular Concentrations of Azithromycin during and after End of Therapy , 2013, Antimicrobial Agents and Chemotherapy.
[13] K. Morimoto,et al. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages , 2011, Biopharmaceutics & drug disposition.
[14] J. Shimada,et al. In Vitro Pharmacokinetic and Pharmacodynamic Evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae , 2010, Antimicrobial Agents and Chemotherapy.
[15] H. Derendorf,et al. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. , 2010, International journal of antimicrobial agents.
[16] P. Tulkens,et al. Cellular Pharmacokinetics of the Novel Biaryloxazolidinone Radezolid in Phagocytic Cells: Studies with Macrophages and Polymorphonuclear Neutrophils , 2010, Antimicrobial Agents and Chemotherapy.
[17] P. McDonald,et al. Phagocyte uptake and transport of azithromycin , 1991, European Journal of Clinical Microbiology and Infectious Diseases.
[18] Sang -Geon Kim,et al. Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate , 2004, Biopharmaceutics & drug disposition.
[19] H. Derendorf,et al. Penetration of Cefaclor Into the Interstitial Space Fluid of Skeletal Muscle and Lung Tissue in Rats , 2001, Pharmaceutical Research.
[20] A. Chella,et al. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. , 2003, The Journal of antimicrobial chemotherapy.
[21] W. Bishai. The in vivo-in vitro paradox in pneumococcal respiratory tract infections. , 2002, The Journal of antimicrobial chemotherapy.
[22] M. Jacobs,et al. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[23] W. L. Hand,et al. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. , 2001, International journal of antimicrobial agents.
[24] S. Hamada,et al. Cytochrome c‐mediated caspase‐9 activation triggers apoptosis in Streptococcus pyogenes‐infected epithelial cells , 2001, Cellular microbiology.
[25] G. Mandell,et al. Uptake, Transport, and Delivery of Antimicrobial Agents by Human Polymorphonuclear Neutrophils , 2001, Antimicrobial Agents and Chemotherapy.
[26] M. Rohde,et al. Two distinct pathways for the invasion of Streptococcus pyogenes in non‐phagocytic cells , 2000, Cellular microbiology.
[27] H. Kotaki,et al. Pharmacodynamic analysis of the electrocardiographic interaction between disopyramide and erythromycin in rats. , 1999, Journal of Pharmacy and Science.
[28] D. Nicolau,et al. Intracellular and extracellular penetration of azithromycin into inflammatory and noninflammatory blister fluid , 1994, Antimicrobial Agents and Chemotherapy.
[29] P. Tulkens,et al. Accumulation, release and subcellular localization of azithromycin in phagocytic and non-phagocytic cells in culture. , 1994, International journal of tissue reactions.
[30] A. Punnia-Moorthy. Evaluation of pH changes in inflammation of the subcutaneous air pouch lining in the rat, induced by carrageenan, dextran and Staphylococcus aureus. , 1987, Journal of oral pathology.